How to Cite
Abstract
Purpose: to determine the dependence of the development of local relapse depending on the chosen tactics of surgical treatment with different biological subtypes of breast cancer.
Materials and methods: molecular taxonomy of breast cancer may improve the prognosis of regional regional recurrence (MPR) and has a great potential for improving decisionmaking regarding local treatment for breast cancer. The review of the world literature, reflecting prospective and retrospective studies on the biological characteristics of breast cancer, is reviewed. The studies reflect such parameters as the degree of malignancy, the age of the patients, the biological subtype of the tumor, and the treatment performed. The development of local and regional regional relapse was assessed depending on the choice of surgical treatment tactics: radical mastectomy and organ-preserving treatment + radiotherapy. The search was limited to 2001, when biological subtypes of breast cancer were identified. Prospective and retrospective studies were evaluated in patients with early operable breast cancer.
Conclusions: young age, tumor malignancy, tumor node size, presence of lymphovascular invasion or lymph node involvement and unfavorable tumor subtypes such as Her2 /neu and triple-negative tumors can be considered as the main predictors of relapse in breast cancer. Tumors having a triple-negative nature have the most aggressive course, this concerns both local, regional relapse, and distant metastasis. Advances in modern neoadjuvant therapy have reduced the overall number of local relapses for all subgroups. Radiation therapy also helps to reduce the risk of local and regional recurrence. At present, there is no single-valued data on the choice of surgical treatment tactics for various biological subtypes, however effective systemic therapy as well as radiotherapy reduces the frequency of local recurrences after performing organ-preserving surgeries in unfavorable tumor subtypes and according to the results of studies, the total and disease-free survival is comparable, as and during mastectomy.References
Давыдов М.И. Статистика злокачественных новообразований в России и странах СНГ в 2013 году // Вестник РОНЦ им. Н.Н. Блохина РАМН. - 2015.
Переводчикова Н.И. Лекарственная терапия рака молочной железы / Н.И. Переводчикова, М.Б. Стенина. - М.: Практика, 2014.
Семиглазов В.Ф., Палтуев Р.М., Семиглазов В.В., Манихас А.Г. и др. Ранний рак молочной железы: прогностическое значение биологических подтипов (анализ кумулятивной базы данных ФГБУ НИИ онкологии им Н.Н Петрова" МИНЗДРАВСОЦРАЗВИТИЯ // Злокачественные опухоли. - 2012. - Т. 2(2). - С. 12-18.
Стенина М.Б., Жукова Л.Г., Королева И.А., Пароконная А.А. и др. Практические рекомендации по лекарственному лечению злокачественных опухолей. Инвазивный рак молочной железы // Злокачественные опухоли. - 2017. - Т. 7(3). - С. 114-115.
Abdulkarim B., Cuartero J., Hanson J., Deschnes J. Increased Risk of Locoregional Recurrence for Women With T1-2N0 Triple-Negative Breast Cancer Treated With Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy // Journal of Clinical Oncology. - 2011. - Vol. 29(21). - P. 2852-2858.
Adkins F., Gonzalez-Angulo A., Lei X., Hernandez-Aya L. Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation // Annals of Surgical Oncology - 2011. - Vol. 18(11). - P. 3164-3173.
Alabdulkareem H., Pinchinat T., Khan S., Landers A. et al. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy // The Breast Journal. - 2017. - P. S183-S184.
Albert J., Buchholz T. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy // Breast Diseases: A Year Book Quarterly. - 2012. - Vol. 23(3). - P. 288-289.
Arvold N., Taghian A., Niemierko A., Abi Raad R. Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy // Journal of Clinical Oncology. - 2011. - Vol. 29(29). - P. 3885-3891.
Beaber E., Buist D., Barlow W., Malone K. Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age // Cancer Research. - 2014. - Vol. 74(15). - P. 4078-4089.
Braunstein L., Taghian A., Niemierko A., Salama L. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy // Breast Cancer Research and Treatment. - 2016. - Vol. 161(1). - P. 173-179.
Chen Q., Wang X., Lin P., Zhang J. The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database // Oncotarget. - 2016. - Vol. 8(3).
Chen S., Huang L., Chen C., Shao Z. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy // Oncotarget. - 2015. - Vol. 6(20).
Engel J., Eckel R., Aydemir Ü. Aydemir. Determinants and prognoses of locoregional and distant progression in breast cancer. International Journal of Radiation // International Journal of Radiation Oncology*Biology*Physics. - 2003. - Vol. 55(5). - P. 1186-1195.
Ferlay J., Soerjomataram I., Dikshit R., Eser S. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2014 // International Journal of Cancer. - 2014. - Vol. 136(5). - P. E359-E386.
Gangi A., Chung A., Mirocha J., Liou D. Breast-Conserving Therapy for Triple-Negative Breast Cancer // JAMA Surgery. - 2014. - Vol. 149(3). - P. 252.
Gnant M., Harbeck N., Thomssen St. Gallen. Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment // Breast Care. - 2017. - Vol. 12(2). - P. 102-107.
Gucalp A., Gupta G., Pilewskie M., Sutton E., Norton L. Advances in managing breast cancer: a clinical update // 2014/F1000Prime Reports. - 2014. - Vol. 6. - P. 66.
Kennecke H., Yerushalmi R., Woods R. et al. Metastatic Behavior of Breast Cancer Subtypes // Journal of Clinical Oncology. - 2010. - Vol. 28(20). - P. 3271-3277.
King T., Radosa J., Eaton A. et al. Evaluation of Local and Distant Recurrence Patterns in Patients with TripleNegative Breast Cancer According to Age // Annals of Surgical Oncology. - 2016. - Vol. 24(3). - P. 698-704.
Laurberg T., Alsner J., Tramm T. et al. Impact of age, intrinsic subtype and local treatment on long-term localregional recurrence and breast cancer mortality among low-risk breast cancer patients // Acta Oncologica. - 2016. - Vol. 56(1). - P. 59-67.
Liedtke C., Mazouni C., Hess K., André F. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer // Journal of Clinical Oncology. - 2008. - Vol. 26(8). - P. 1275-1281.
Lowery A., Kell M., Glynn R. et al. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Research and Treatment // Breast Cancer Research and Treatment. - 2011. - Vol. 133(3). - P. 831-841.
Mannino М., Yarnold J. Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: Can radiotherapy ever be safely withheld? // Radiotherapy and Oncology. - 2009. - Vol. 90(1). - P. 14-22.
Moran M. Radiation therapy in the locoregional treatment of triple-negative breast cancer // The Lancet Oncology. - 2015. - Vol. 16(3). - P. e113-e122.
Nguyen P., Taghian A., Katz M. et al. Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy // Journal of Clinical Oncology. - 2009. - Vol. 26(14). - P. 2373 -2378.
Prat A., Cheang M., Martin M., Parker J. Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer // Journal of Clinical Oncology. - 2011. - Vol. 31(2). - P. 203-209.
Romond E.H., Perez E.A., Bryant J. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-posi-tive breast cancer // N. Engl. J. Med. - 2005. - Vol. 353. - P. 1673-1684.
Senn H. St. Gallen Consensus 2013: Optimizing and Personalizing Primary Curative Therapy of Breast Cancer Worldwide // Breast Care. - 2013. - Vol. 8(2). - P. 101-101.
Siponen E., Joensuu H., Vironen J., Heikkil P. Ipsilateral breast recurrence after breast conserving surgery in patients with small (
Tran B., Bedard P. Luminal-B breast cancer and novel therapeutic targets // Breast Cancer Research. -2011. - Vol. 13(6).
Viale G., Regan M., Maiorano E. et al. Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98 // Journal of Clinical Oncology. - 2007. - Vol. 25(25). - P. 3846-3852.
Wang J., Xie X., Wang X., Tang J. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: A meta-analysis // Surgical Oncology. - 2013. - Vol. 22(4). - P. 247-255.
Wong F., Chua E. Hormone Receptors and HER-2 Status as Surrogates for Histological Subtypes Prognosticate for Disease Control in Node Negative Asian Breast Cancer Patients Treated with Breast Conservation Therapy // International Journal of Radiation Oncology*Biology*Physics. - 2011. - Vol. 75(3). - P. S183-S184.
Wu X., Baig A., Kasymjanova G. et al. Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. - 2016.
Yang T., Morrow M., Modi S. et al. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation // Annals of Surgical Oncology. - 2015. - Vol. 22(S3). - P 495501.
Zumsteg Z., Morrow M., Arnold B., Zheng J. Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer // Annals of Surgical Oncology. - 2013. - Vol. 20(11). - P 3469-3476.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018